Literature DB >> 10781437

TRAIL expression in vascular smooth muscle.

B R Gochuico1, J Zhang, B Y Ma, A Marshak-Rothstein, A Fine.   

Abstract

TRAIL is a cell-associated tumor necrosis factor-related apoptosis-inducing ligand originally identified in immune cells. The ligand has the capacity to induce apoptosis after binding to cell surface receptors. To examine TRAIL expression in murine vascular tissue, we employed in situ hybridization and immunohistochemistry. In these studies, we found that TRAIL mRNA and protein were specifically localized throughout the medial smooth muscle cell layer of the pulmonary artery. Notably, a similar pattern of expression was observed in the mouse aorta. Consistent with these findings, we found that cultures of primary human aorta and pulmonary artery smooth muscle cells express abundant TRAIL mRNA and protein. We also found that these cells and endothelial cells undergo cell lysis in response to exogenous addition of TRAIL. Last, we confirmed that TRAIL specifically activated a death program by confirming poly(ADP ribose) polymerase cleavage. Overall, we believe that these findings are relevant to understanding the factors that regulate cell turnover in the vessel wall.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781437     DOI: 10.1152/ajplung.2000.278.5.L1045

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  17 in total

1.  TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.

Authors:  Suizhao Wang; Wenhong Ren; Jeffery Liu; Guy Lahat; Keila Torres; Gonzalo Lopez; Alexander J Lazar; Andrea Hayes-Jordan; Kebin Liu; Jim Bankson; John D Hazle; Dina Lev
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

2.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism.

Authors:  Haixu Yu; Wei Rong; Jie Yang; Jie Lu; Ke Ma; Zhuohui Liu; Hui Yuan; Lei Xu; Yulin Li; Zhi-Cheng Jing; Jie Du
Journal:  J Clin Med       Date:  2022-07-05       Impact factor: 4.964

3.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

4.  Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.

Authors:  Paola Secchiero; Arianna Gonelli; Edvige Carnevale; Federica Corallini; Clara Rizzardi; Serena Zacchigna; Mauro Melato; Giorgio Zauli
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

5.  The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.

Authors:  L B Pritzker; M Scatena; C M Giachelli
Journal:  Mol Biol Cell       Date:  2004-04-02       Impact factor: 4.138

Review 6.  Osteoprotegerin, vascular calcification and atherosclerosis.

Authors:  Ann Van Campenhout; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2008-10-09       Impact factor: 5.162

7.  TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells.

Authors:  G Cantarella; N Risuglia; R Dell'eva; L Lempereur; A Albini; G Pennisi; G M Scoto; D N Noonan; R Bernardini
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

8.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10

9.  Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension.

Authors:  Allan Lawrie; Elizabeth Waterman; Mark Southwood; David Evans; Jay Suntharalingam; Sheila Francis; David Crossman; Peter Croucher; Nicholas Morrell; Christopher Newman
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

10.  Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.

Authors:  Abdul G Hameed; Nadine D Arnold; Janet Chamberlain; Josephine A Pickworth; Claudia Paiva; Sarah Dawson; Simon Cross; Lu Long; Lan Zhao; Nicholas W Morrell; David C Crossman; Christopher M H Newman; David G Kiely; Sheila E Francis; Allan Lawrie
Journal:  J Exp Med       Date:  2012-10-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.